Table 2. Multivariable cox regression analysis in the whole ICC-MVI patients (n=223).
| Variable | Tumor recurrence | OS | |||||
|---|---|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | HR | 95% CI | ||
| CA 19-9, U/mL, ≥39 vs. <39 | 0.037 | 1.38 | 1.02–1.87 | 0.005 | 1.53 | 1.13–2.05 | |
| Tumor diameter (cm), >5 vs. ≤5 | 0.248 | 1.21 | 0.88–1.66 | 0.019 | 1.46 | 1.06–2.00 | |
| Tumor number, Multiple vs. Solitary | 0.209 | 1.25 | 0.88–1.75 | 0.002 | 1.68 | 1.21–2.33 | |
| Direct invasion, Yes vs. No | 0.386 | 1.29 | 0.73–2.27 | 0.030 | 1.81 | 1.06–3.10 | |
| Regional nodal metastasis | |||||||
| Nx vs. N0 | 0.399 | 0.86 | 0.60–1.23 | 0.472 | 0.88 | 0.62–1.25 | |
| N1 vs. N0 | 0.026 | 1.54 | 1.05–2.26 | 0.009 | 1.63 | 1.13–2.36 | |
| Adjuvant TACE, Yes vs. No | 0.177 | 0.79 | 0.56–1.11 | 0.208 | 0.81 | 0.58–1.12 | |
ICC-MVI, intrahepatic cholangiocarcinoma involving microvascular invasion; OS, overall survival; HR, hazard ratio; CA19-9, carbohydrate antigen 19-9; N0, no regional lymph node metastasis; Nx, regional lymph node metastasis cannot be assessed; N1, regional lymph node metastasis present; TACE, transarterial chemoembolization.